In the Claims:

The listing of claims will replace all prior versions and listings of claims in the application.

Listings of claims:

1. (Original) A compound of Formula (I),



Formula (I)

wherein

A represents a direct bond or optionally substituted C_{1-5}alkylene;

B is a group of Formula (II):



Formula (II);

wherein at position (a) Formula (II) is attached to the nitrogen atom and the group **X** is attached to $\mathbf{R^8}$;

$\mathbf{R^1}$ represents hydrogen; optionally substituted C_{1-8}alkyl; or $(CH_2)_b$-$\mathbf{R^a}$, wherein $\mathbf{R^a}$ represents C_{3-8}cycloalkyl and **b** is zero or an integer from 1 to 6;

$\mathbf{R^2}$ represents an optionally substituted mono- or bi-cyclic aromatic ring structure wherein the optional substituents are selected from cyano, $N\mathbf{R^3R^{3a}}$, optionally substituted C_{1-8}alkyl, optionally substituted C_{1-8}alkoxy or halo;

R^3 and R^{3a} are independently selected from hydrogen; optionally substituted C_{1-8}alkyl and optionally substituted aryl;

R^4 is hydrogen;

R^5 is selected from an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S; or a group of formula **III-a**; **III-b**; **III-c**; **III-d**; **III-e**; **III-f**, **III-g** , **III-h**, **III-i**, **III-j**, **III-k** or **III-l**;



wherein **het** represents an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S;

R^6 and R^{6a}, are independently selected from hydrogen and optionally substituted C_{1-8}alkyl; or R^6 and R^{6a} together represent carbonyl;

R^7 represents hydrogen or optionally substituted C_{1-8}alkyl;

or  together form an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 3 further heteroatoms

independently selected from O, N and S, and $\mathbf{R^{6a}}$ represents hydrogen and optionally substituted C_{1-8}alkyl;

X and $\mathbf{R^8}$ are selected from:

(i) **X** represents N and $\mathbf{R^8}$ is selected from:
cyano, hydrogen, hydroxy, -O-$\mathbf{R^b}$, -C(O)-$\mathbf{R^b}$, –N$\mathbf{R^b R^c}$ –C(O)O-$\mathbf{R^b}$, –CON$\mathbf{R^b R^c}$ or NH-C(O)-$\mathbf{R^b}$, where $\mathbf{R^b}$ and $\mathbf{R^c}$ are independently selected from hydrogen and C_{1-4}alkyl optionally substituted with hydroxy, amino, N-C_{1-4}alkylamino, N,N-di-C_{1-4}alkylamino, HO-C_{2-4}alkyl-NH- or HO-C_{2-4}alkyl-N(C_{1-4}alkyl)-;

(ii) **X** represents CH and $\mathbf{R^8}$ represents NO_2; and

(iii) =**X**-$\mathbf{R^8}$ represents =O;

$\mathbf{R^{11}}$ is a group of the formula: N($\mathbf{R^9 R^{10}}$) wherein $\mathbf{R^9}$ represents hydrogen, optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally-substituted C_{1-8}alkyl and $\mathbf{R^{10}}$ represents hydrogen or optionally substituted C_{1-8}alkyl; or

the structure N($\mathbf{R^9 R^{10}}$) represents an optionally-substituted 3- to 10 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S;

$\mathbf{R^{12}}$ and $\mathbf{R^{12a}}$ are independently selected from hydrogen or optionally substituted C_{1-8}alkyl; or $\mathbf{R^{12}}$ and $\mathbf{R^{12a}}$ together with the carbon to which they are attached form an optionally substituted 3 to 7-membered cycloalkyl ring;

$\mathbf{R^{13}}$ and $\mathbf{R^{14}}$ are selected from:

(i) $\mathbf{R^{13}}$ is selected from hydrogen; optionally substituted C_{1-8}alkyl; optionally substituted aryl; -$\mathbf{R^d}$-Ar, where $\mathbf{R^d}$ represents C_{1-8}alkylene and Ar represents optionally substituted aryl; and optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; and $\mathbf{R^{14}}$ is selected from hydrogen; optionally substituted C_{1-8}alkyl and optionally substituted aryl;

(ii) where $\mathbf{R^5}$ represents a group of formula **III-a , III-b, III-i** or **III-k**, then the group $N\mathbf{R^{13}}(-\mathbf{R^{14}})$ represents an optionally substituted 3- to 8-membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; or

(iii) where $\mathbf{R^5}$ represents structure **III-e**, then the group  represents an optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 4 heteroatoms independently selected from O, N and S;
$\mathbf{R^{17}}$ is selected from: hydrogen and C_{1-4}alkyl;
or a salt, pro-drug or solvate thereof.

2. (Original) A compound according to Claim 1 wherein $\mathbf{R^9}$ represents hydrogen, optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally-substituted C_{1-8}alkyl and $\mathbf{R^{10}}$ represents hydrogen or optionally substituted C_{1-8}alkyl wherein the optional substituents on aryl, the heterocyclic ring and C_{1-8}alkyl are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3- to 8- membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S, $-O-\mathbf{R^b}$, $C(O)N\mathbf{R^b}\mathbf{R^c}$, $-N\mathbf{R^b}\mathbf{R^c}$, $-N\mathbf{R^c}C(O)-\mathbf{R^b}$, $-C(O)N\mathbf{R^b}\mathbf{R^c}$, $-N\mathbf{R^c}S(O_{0-2})\mathbf{R^b}$, $-S(O_{0-2})\mathbf{R^b}$, wherein $\mathbf{R^b}$ and $\mathbf{R^c}$ are as defined in Claim 1.

3. (Original) A compound according to Claim 2 wherein $\mathbf{R^9}$ is a C_{1-6}alkyl group substituted by pyridyl, thienyl, piperidinyl, imidazolyl, triazolyl, thiazolyl, pyrrolidinyl, piperazinyl, morpholinyl, imidazolinyl, benztriazolyl, benzimidazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, oxazolyl, furanyl, pyrrolyl, 1,3-dioxolanyl or 2-azetinyl, each of which is optionally substituted as defined in Claim 2.

4. (Original) A compound according to Claim 1 wherein the structure $N(\mathbf{R}^9\mathbf{R}^{10})$ represents an optionally-substituted 3- to 10 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S.

5. (Original) A compound according to Claim 4 wherein the 3- to 10 membered heterocyclic ring is optionally substituted by one of more groups selected from $\mathbf{R}^{15}$ wherein
$\mathbf{R}^{15}$ represents the group $\mathbf{R}^{15a}$-**Z**- wherein
$\mathbf{R}^{15a}$ is selected from optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally substituted C_{1-4}alkyl and
Z is selected from a a direct bond, $-(CH_2)_{s1}-$, $-(CH_2)_{s1}-O-(CH_2)_{s2}-$, $-(CH_2)_{s1}-C(O)-(CH_2)_{s2}-$, $-(CH_2)_{s1}-S(O_n)-(CH_2)_{s2}-$, $-(CH_2)_{s1}-N(\mathbf{R}^{18})-(CH_2)_{s2}-$, $-(CH_2)_{s1}-C(O)N(\mathbf{R}^{18})-(CH_2)_{s2}-$, $-(CH_2)_{s1}-N(\mathbf{R}^{18})C(O)-(CH_2)_{s2}-$, $-(CH_2)_{s1}-N(\mathbf{R}^{18})C(O)N(\mathbf{R}^{18})-(CH_2)_{s2}-$, $-(CH_2)_{s1}-OC(O)-(CH_2)_{s2}-$, $-(CH_2)_{s1}-C(O)O-(CH_2)_{s2}-$, $-(CH_2)_{s1}-N(\mathbf{R}^{18})C(O)O-(CH_2)_{s2}-$, $-(CH_2)_{s1}-OC(O)N(\mathbf{R}^{18})-(CH_2)_{s2}-$, $-(CH_2)_{s1}-OS(O_n)-(CH_2)_{s2}-$, or $-(CH_2)_{s1}-S(O_n)-O-(CH_2)_{s2}-$, $-(CH_2)_{s1}-S(O)_2N(\mathbf{R}^{18})-(CH_2)_{s2}-$, $-(CH_2)_{s1}-N(\mathbf{R}^{18})S(O)_2-(CH_2)_{s2}-$; wherein
the $-(CH_2)_{s1}-$ and $-(CH_2)_{s2}-$ groups are independently optionally substituted by hydroxy or C_{1-4}alkyl and **s1** and **s2** are independently an integer from 0 to 2, wherein **s1**+**s2** is less than or equal to 2 and
$\mathbf{R}^{18}$ is selected from hydrogen or C_{1-4}alkyl;
wherein the optional substituents on aryl, a heterocyclic ring or C_{1-4}alkyl are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3- to 8- membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S, -O-$\mathbf{R}^g$, -C(O)-$\mathbf{R}^g$, $-C(O)N\mathbf{R}^g\mathbf{R}^h$, $--N\mathbf{R}^g\mathbf{R}^h$, $-N\mathbf{R}^hC(O)-\mathbf{R}^g$, $-C(O)N\mathbf{R}^g\mathbf{R}^h$, $-N\mathbf{R}^hS(O_{0-2})\mathbf{R}^g$, $-S(O_{0-2})\mathbf{R}^g$, wherein $\mathbf{R}^g$ and $\mathbf{R}^g$ are independently selected from: heterocyclyl, hydrogen and C_{1-4}alkyl optionally substituted with hydroxy, amino,

N-C_{1-4}alkylamino, N,N-di-C_{1-4}alkylamino, HO-C_{2-4}alkyl-NH- or HO-C_{2-4}alkyl-N(C_{1-4}alkyl)-. .

6. (Original) A compound according to Claim 5, wherein **Z** is selected from a direct bond or carbonyl.

7. (Currently Amended) A compound according to claim 1~~any one of the preceding claims~~ wherein $\mathbf{R^5}$ is selected from a group of formula **III-a** , **III-g**, **III-h**, **III-i** or **III-j**:



III-a



III-g



III-h



III-i



III-j

8. (Currently Amended) A compound according to claim 1~~any one of the preceding claims~~ wherein:
(a) **X** represents N and $\mathbf{R^8}$ represents cyano or –C(O)O-$\mathbf{R^b}$; wherein $\mathbf{R^b}$ is as defined in Claim 1, or
(b) **X** represents N and $\mathbf{R^8}$ represents hydrogen.

9. (Currently Amended) A compound according to claim 1~~any one of the~~ preceding claims wherein $\mathbf{R^2}$ is selected from an optionally substituted monocyclic aromatic ring structure wherein the optional substituents are selected from cyano, N$\mathbf{R^e R^f}$, optionally substituted C_{1-8}alkyl, optionally

substituted C_{1-8}alkoxy or halo wherein $\mathbf{R^e}$ and $\mathbf{R^f}$ are independently selected from hydrogen, C_{1-6}alkyl or aryl.

10. (Currently Amended) A compound according to claim 1~~any one of the~~ preceding claims wherein $\mathbf{R^1}$ is hydrogen.

11. (Original) A compound selected from:
2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-
4-[1S-methyl-2-(N'-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboxi midamido) ethyl]-5-(3,5-dimethylphenyl)--6*H*-thieno[2,3-*b*]pyrrole;
2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-
4-[2-(N'-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido) ethyl]-5-(3,5-dimethylphenyl)--6*H*-thieno[2,3-*b*]pyrrole;
2-(2-pyrrolidin-1-yl-1,1-dimethyl-2-oxoethyl)-
4-[1S-methyl-2-(N'-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboxi midamido) ethyl]-5-(3,5-dimethylphenyl)--6*H*-thieno[2,3-*b*]pyrrole;
2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-
4-[1S-methyl-2-(N'-isopropoxycarbonyl-4-tetrahydropyran-4-yl-piperidin-1-ylcarboximidamido)ethyl]-5-(3,5-dimethylphenyl)--6*H*-thieno[2,3-*b*]pyrrole;
2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-
4-[1S-methyl-2-(3-pyrid-4-yl-pyrrolidin-1-ylcarbonyl)ethyl]-5-(3,5-dimethylphenyl)--6*H*-thieno[2,3-*b*]pyrrole;
2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-
4-[1S-methyl-2-(N'-ethoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-yl carboximidamido) ethyl]-5-(3,5-dimethylphenyl)--6H-thieno[2,3-b]pyrrole;
or a salt, pro-drug or solvate thereof.

12. (Cancelled)

13. (Currently amended) A pharmaceutical formulation comprising a compound, or salt, pro-drug or solvate thereof, according to claim 1~~any one of Claims 1 to 11~~and a pharmaceutically acceptable diluent or carrier.

14. (Currently amended) A method of antagonising gonadotropin releasing hormone activity, the method comprising administering ~~Use of~~ a compound according to claim 1, or salt, pro-drug or solvate thereof, to a patient.~~according to any one of Claims 1 to 11, in the manufacture of a medicament for administration to a patient, for therapeutically treating and/or preventing a sex hormone related condition in the patient.~~

15. (Currently amended) A process of producing a compound, or salt, pro-drug or solvate thereof, according to claim 1~~any one of Claims 1 to 11~~, wherein the process comprises a reaction step selected from any one of steps (a) to (f):-

(a) Reaction of a compound of formula **XXXII** as follows



XXXII **XXXIII**

(b) Cleavage of the cyano group of a compound of formula **XXXIII** in the presence of acid to produce a compound of formula **XXXIV**



XXXIV

(c) Reaction of a compound of formula **XXXV** as follows



XXXV **XXXVI**

(d) Reaction of a compound of formula **XXXVII** as follows



XXXVII **XXXVIII**

(e) Reaction of a compound of formula **XXXIX** as follows



XXXIX XXXX

(f) to form a compound wherein **X** is nitrogen and Reaction of a compound of formula XXXXI as follows



XXXXI XXXXII

and thereafter if necessary:

i) converting a compound of the Formula (I) into another compound of the Formula (I);

ii) removing any protecting groups;

iii) forming a salt, pro-drug or solvate.